News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Hematologic Oncology

Latest News

Video Series

Ashkan Emadi, MD, PhD

Dr Emadi on Initial Responses With Venetoclax Plus PegC in R/R AML

A panel of 3 experts on ALL

The Future of AYA ALL

A panel of 3 experts on ALL

The Potential of Modified Treatment Regimens in AYA ALL

A panel of 3 experts on ALL

CALBG 10403 in AYA ALL

A panel of 3 experts on ALL

Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL

A panel of 3 experts on ALL

ALL AYA: Coordination of Care

A panel of 3 experts on ALL

Asparaginase Erwinia Chrysanthemi: Side Effects and Hypersensitivity Reactions

A panel of 3 experts on ALL

AYA ALL: Role of Asparaginase Erwinia Chrysanthemi

A panel of 3 experts on ALL

AYA ALL: Pediatric and Adult Inspired Regimens

A panel of 3 experts on ALL

AYA ALL: Overview and Risk Stratification

Latest Videos

Image Credit: © TheWaterMeloonProjec - stock.adobe.com

Dr Herrera on Important Safety Data and Considerations for Nivolumab Plus AVD in Classical Hodgkin Lymphoma

Image Credit: © Bipul Kumar - stock.adobe.com

Dr Loghavi on Key Updates to the WHO Diagnostic Criteria for AML

Image Credit: © Bipul Kumar - stock.adobe.com

Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice

Image Credit: © TheWaterMeloonProjec - stock.adobe.com

Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma

$Tara Graff, DO, details the role of CAR T-cell therapy in the relapsed/refractory diffuse large B-cell lymphoma treatment paradigm.$

Dr Graff on the Utilization of CAR T-Cell Therapy in R/R DLBCL

Image Credit: © TheWaterMeloonProjec - stock.adobe.com

Dr Park on the Role and Benefits of Evaluating MRD in ALL

Image Credit: © Oleksandr - stock.adobe.com

Dr Park on Emerging Data Shaping the Evolving Role of Obe-Cel in R/R ALL

Daniel J. DeAngelo, MD, PhD, discusses debate points in acute lymphoblastic leukemia care that future research could address.

Dr DeAngelo on Key Questions to Address in Acute Lymphoblastic Leukemia Management

Alexandra Rojek, MD

Dr Rojek on Improving CAR T-Cell Therapies in Lymphoma

Sonali M. Smith, MD

Dr Smith on Translating CAR T-Cell Therapies From Hematologic to Solid Malignancies

Shorts

OncLive News Roundup for the Week of 5/17

OncLive News Roundup for the Week of 5/17

17 days ago

by

Chris Ryan

Stefan K. Barta, MD, MS

Breaking Down Mogamulizumab-Associated Rashes in CTCL

19 days ago

by

Stefan K. Barta, MD, MS

OncLive News Roundup for the Week of 5/10

OncLive News Roundup for the Week of 5/10

22 days ago

by

Chris Ryan(+1 more)

Alex Herrera, MD

Breaking Down the FDA Approval of Nivolumab AVD for Untreated Classical Hodgkin Lymphoma

25 days ago

by

Alex Herrera, MD

Sanam Loghavi, MD

Outlining the Importance of Updated WHO Diagnostic Criteria for AML

a month ago

by

Sanam Loghavi, MD

Courtney DiNardo, MD, MSCE

Expert Insights on FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML

a month ago

by

Courtney DiNardo, MD, MSCE(+1 more)

Managing Mogamulizumab-Associated Rash in CTCL

Managing Mogamulizumab-Associated Rash in CTCL

a month ago

by

Brad Haverkos, MD

OncLive News Roundup for the Week of 5/3

OncLive News Roundup for the Week of 5/3

a month ago

by

Chris Ryan(+1 more)

Ashley Sumrall, MD, FACP, FASCO

Breaking Down the Current State of CAR T-Cell Therapies in PCNSL

a month ago

by

Ashley Sumrall, MD

Sagar S. Patel, MD

Breaking Down the Basics of Orca-T and its Development

2 months ago

by

Sagar Patel, MD

Podcasts

Michael J. Mauro, MD

TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD

Quinto Gesiotto, MD, discusses optimal ponatinib dosing strategies and evolving TKI sequencing considerations in chronic myeloid leukemia.

Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD

Jae Park, MD

Real-World Analyses Help Make Sense of Multiple Approved CAR T-Cell Therapies for ALL: With Jae Park, MD

Wendy Stock, MD

ASH Guidelines Provide Key Recommendations for AYA Acute Lymphoblastic Leukemia Management: With Wendy Stock, MD

Colin Vale, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD

Sonali Smith, MD

Exploring CAR T in Solid Tumors, Clinical Trials, and Cancer Incidence Questions

Nicholas Short, MD

February 13, 2026

Comprehensive Ph+ ALL Paradigm Knowledge Informs Frontline Ponatinib Use: With Nicholas Short, MD

Tycel Phillips, MD, associate professor, Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope

January 30, 2026

Long-Term Epcoritamab Data Show Durable Responses and Confirmed Safety in LBCL: With Tycel Phillips, MD

Lorenzo Falchi, MD, medical oncologist/hematologist, assistant attending physician, Lymphoma Service, Memorial Sloan Kettering Cancer Center

January 15, 2026

FDA Approval Insights: Epcoritamab Plus Rituximab/Lenalidomide for Relapsed/Refractory Follicular Lymphoma: With Lorenzo Falchi, MD

Sarah Rutherford, MD, associate professor, clinical medicine, Division of Hematology/Oncology, Weill Cornell Medicine

December 2, 2025

ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD

CME Content

10th Annual Live Medical Crossfire®: Hematologic Malignancies

In-Person + Virtual Event

10th Annual Live Medical Crossfire®: Hematologic Malignancies

July 11-12, 2026

Iowa Oncology Society

Iowa Oncology Society

2 Sessions are Available!

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Seth A. Wander, MD, PhD; Ruta D. Rao, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Seth A. Wander, MD, PhD; Kate Baxstrom, MD

Wyoming State Oncology Society

Wyoming State Oncology Society

2 Sessions are Available!

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

North Carolina Oncology Association

North Carolina Oncology Association

2 Sessions are Available!

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD; Sylvia L. Asa, MD, PhD

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; Ulka Vaishampayan, MD, FASCO

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Benjamin P. Levy, MD; Sarah Goldberg, MD, MPH; Jacob Sands, MD; Helena Yu, MD

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Seth A. Wander, MD, PhD; Yang Liu, MD

Louisiana Oncology Society

Louisiana Oncology Society

2 Sessions are Available!

Missouri Oncology Society

Missouri Oncology Society

2 Sessions are Available!

New Mexico Society of Clinical Oncology

New Mexico Society of Clinical Oncology

2 Sessions are Available!

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

1 Session is Available!

Indiana Oncology Society

Indiana Oncology Society

2 Sessions are Available!

Arkansas Association of Cancer Professionals

Arkansas Association of Cancer Professionals

1 Session is Available!

Rhode Island Oncology Society

Rhode Island Oncology Society

3 Sessions are Available!

Kentucky Society of Clinical Oncology

Kentucky Society of Clinical Oncology

2 Sessions are Available!

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Empire State Hematology & Oncology Society (New York)

Empire State Hematology & Oncology Society (New York)

3 Sessions are Available!

Minnesota Society of Clinical Oncology

Minnesota Society of Clinical Oncology

1 Session is Available!

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

West Virginia Oncology Society

West Virginia Oncology Society

1 Session is Available!

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Optimizing Treatment for Biliary Tract Cancers

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Cross-Disease Integration of Immunotherapy Innovations

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

More News

DLBCL | Image Credit: © Oleksandr - stock.adobe.com

frontMIND Results: Tafasitamab-Based Combo Yields Significant PFS Benefit Over R-CHOP in Frontline High-Risk DLBCL

May 31st 2026

Tafasitamab plus lenalidomide and R-CHOP showed significant PFS improvements compared with R-CHOP alone in diffuse large B-cell lymphoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

OncLive Weekly News Quiz (5/29/2026): Test Your Knowledge on Updates in NMIBC, BPDCN, and NSCLC

ByOncLive Staff

May 29th 2026

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

FDA

FDA Approves Pivekimab Sunirine for Blastic Plasmacytoid Dendritic Cell Neoplasm

May 27th 2026

The FDA has approved pivekimab sunirine-pvzy (Decnupaz) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm.

Generic formulations of cancer drugs | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

FDA Product-Specific Guidelines Guide Proper Evaluation of Generic Bioequivalence in Key Oncology Drugs

May 25th 2026

The FDA has published new sets of product-specific guidelines for investigating generic cancer treatments to guide proper evaluation of bioequivalence.

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

Five Under 5: Top Oncology Videos for the Week of 5/17

ByOncLive Staff

May 24th 2026

The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

The OncFive: Top Oncology Articles for the Week of 5/17

ByOncLive Staff

May 23rd 2026

The FDA approved Dato-DXd for PD-1/PD-L1–ineligible triple-negative breast cancer, granted priority review to sevabertinib in HER2-mutant NSCLC, and more.

ASCO 2026 | Image Credit: © Brighting Collection - stock.adobe.com

Polls Reveal Picks for Top Hematologic Oncology Abstracts at ASCO 2026

ByOncLive Staff

May 22nd 2026

Poll results reflected some of the most anticipated presentations and fields of interest in hematologic oncology at the 2026 ASCO Annual Meeting.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

OncLive Weekly News Quiz (5/22/2026): Test Your Knowledge on Updates in Bladder Cancer, NSCLC, and AML

ByOncLive Staff

May 22nd 2026

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Image credit: Om.Nom.Nom - stock.adobe.com

Frontline Combos Take the Spotlight: Previewing the Top Hematologic Oncology Presentations at ASCO 2026

ByChris Ryan,Riley Kandel

May 21st 2026

Hematologic oncology experts preview the top ASCO 2026 abstracts to watch in myeloma, MPNs, large B-cell lymphoma, and more.

FDA

CLN-049 Nets FDA Orphan Drug Designation for in R/R AML

May 20th 2026

The FDA granted orphan drug designation to CLN-049 for relapsed or refractory acute myeloid leukemia based on data from early-phase studies.

Giants of Cancer Care

Giants of Cancer Care: OncLive Honors 14 Pioneers

ByOncLive Staff

May 18th 2026

OncLive announced the 2026 Giants of Cancer Care winners.

AML | Image Credit: © Om.Nom.Nom - stock.adobe.com

Annamycin Plus Cytarabine Delivers Promising Response Rates in R/R AML

May 18th 2026

Second-line annamycin plus cytarabine injections demonstrated promising responses in patients with relapsed or refractory acute myeloid leukemia.

OncLive On Air Podcast Recap

Revisit Every OncLive On Air Episode From April 2026

ByAshling Wahner

May 18th 2026

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in April 2026.

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

Five Under 5: Top Oncology Videos for the Week of 5/10

ByOncLive Staff

May 17th 2026

The top 5 OncLive TV videos of the week cover insights in breast cancer, acute myeloid leukemia, bladder cancer, multiple myeloma, and melanoma.

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

The OncFive: Top Oncology Articles for the Week of 5/10

ByOncLive Staff

May 16th 2026

The FDA approved T-DXd in early HER2+ breast cancer, adjuvant atezolizumab in MRD+ MIBC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

OncLive Weekly News Quiz (5/15/2026): Did You Catch 3 New FDA Oncology Approvals?

ByOncLive Staff

May 15th 2026

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Alexey Danilov, MD, PhD

Consensus Recommendations Address Key Controversies in Lymphoma Management

May 13th 2026

Alexey Danilov, MD, PhD, and Tycel Phillips, MD, highlight key consensus viewpoints in lymphoma published from the 2025 Bridging the Gaps meeting.

Secondary Primary Malignancies With Tazemetostat: ©catalin - stock.adobe.com

FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma

May 12th 2026

The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Five Under 5: Top Oncology Videos for the Week of 5/3

ByOncLive Staff

May 10th 2026

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updates

ByOncLive Staff

May 8th 2026

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease | Image Credit: © Om.Nom.Nom - stock.adobe.com

FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease

May 7th 2026

The FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.

Iopofosine I 131 in Waldenström Macroglobulinemia | Image Credit: © Bipul Kumar - stock.adobe.com

Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström Macroglobulinemia

May 5th 2026

Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.

R/R PTCL | Image Credit: © Motion Pics - stock.adobe.com

Duvelisib Yields Strong Efficacy, Durable Responses in R/R PTCL

May 4th 2026

Duvelisib demonstrated deep, durable responses and promising efficacy data across peripheral T-cell lymphoma subgroups.

Hematologic malignancies | Image Credit: © TheWaterMeloonProjec - stock.adobe.com

FDA Grants RMAT Designation to Orca-Q for High-Risk Hematologic Malignancies

May 2nd 2026

Orca-Q Receives FDA RMAT Designation for High-Risk Hematologic Malignancies.

CTCL | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

DMC Recommends Halting Phase 3 Confirmatory Study of HyBryte in CTCL Due to Futility

April 28th 2026

A data monitoring committee recommended halting the phase 3 FLASH2 trial investigating HyBryte in CTCL due to futility.

Trending on OncLive

Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer

KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC

GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026

Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma

May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates